ETFIQData as of Nov 13, 2026. · etfiq.com/funds/labd

LABD Fact Sheet: Direxion Daily S&P Biotech Bear 3X ETF

Share
$7.42
close, Nov 13, 2026

Over the year to Nov 13, 2026, LABD returned −72.8% in total and charged 1.07% a year.

1-year total return
−72.8%
XBI +35.1% to Nov 13, 2026
Expense ratio
1.07%
a year
Net assets
$79m
on Nov 12, 2026
Net flow, last 5 trading days
+$29.3m
daily basis to Nov 12, 2026

Growth of $10,000, 1 year

LABD $2,721 −72.8% · XBI $13,509 +35.1% · Total return, distributions reinvested, Nov 13, 2025 to Nov 13, 2026.

Returns

WindowTotal return
1 month−14.1%
3 months−0.9%
Year to date−64.0%
1 year−72.8%
3 years−96.0%

Total return, distributions reinvested, each window to Nov 13, 2026.

Facts

Aims to return three times the opposite of the daily move of biotech (XBI) · First traded May 28, 2015 · Benchmark XBI

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, LABD Fact Sheet: Direxion Daily S&P Biotech Bear 3X ETF. Data as of Nov 13, 2026. https://etfiq.com/funds/labd/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/labd.